GCP
LUMO

GSA Capital Partners’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

GSA Capital Partners’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,684
Closed -$1.34M – 1866
2017
Q3 		$1.34M Buy
14,684
+12,736
+654% +$977K 0.09% 334
2017
Q2 		$129K Sell
1,948
-941
-33% -$116K 0.01% 1567
2017
Q1 		$627K Sell
2,889
-4,844
-63% -$692K 0.03% 956
2016
Q4 		$715K Buy
7,733
+2,255
+41% +$254K 0.04% 753
2016
Q3 		$740K Buy
+5,478
New +$544K 0.04% 813
2016
Q2 		– Sell
-4,594
Closed -$753K – 1958
2016
Q1 		$753K Sell
4,594
-2,692
-37% -$546K 0.05% 718
2015
Q4 		$2.39M Buy
7,286
+389
+6% +$127K 0.12% 194
2015
Q3 		$2.23M Buy
6,897
+1,595
+30% +$701K 0.11% 219
2015
Q2 		$2.11M Buy
5,302
+3,606
+213% +$1.53M 0.08% 336
2015
Q1 		$835K Buy
+1,696
New +$657K 0.03% 1015
2014
Q1 		– Sell
-1,018
Closed -$202K – 1841
2013
Q4 		$202K Buy
+1,018
New +$181K 0.02% 1461

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSA Capital Partners's LUMO Position: Q4 2017 in Review

GSA Capital Partners sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 14,684 shares — an estimated $1.34M sold.

GSA Capital Partners first reported a position in LUMO in Q4 2013 and held it in 11 quarters. The position peaked at $2.39M in Q4 2015. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • GSA Capital Partners reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • GSA Capital Partners sold 14,684 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $1.34M.
  • GSA Capital Partners first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 11 quarters.
  • GSA Capital Partners's Lumos Pharma, Inc. Common Stock position peaked at $2.39M in Q4 2015.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on GSA Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.